JNJ Sees Double-Digit Growth with Focused Portfolio and Pipeline Innovation
Johnson & Johnson (JNJ) recently participated in the Morgan Stanley 24th Annual Global Healthcare Conference. The event highlighted the company's focused portfolio, which is driving accelerated growth and robust pipeline progress.
The conference emphasized that JNJ's advanced therapies in oncology and immunology are key contributors to its double-digit growth targets through the decade. Additionally, new product launches and MedTech innovation are expected to support these targets.